Original title: 02219.HK price stabilization action and exercise of over-allotment options at the end of the price stabilization period Source: Caihua Network

[Caihua Social News] 02219.HK announced that the over-allotment option mentioned in the prospectus had been partially exercised by the joint global coordinator (for itself and on behalf of the international underwriter) on July 29, 2021, involving a total of 20125000 additional shares, accounting for about 14.64% of the new shares and about 11.77% of the offer shares initially available for subscription under the global offering before any exercise of the over-allotment option. The over-allotment shares will be issued at HK $10.60 per offer share (excluding brokerage commission of 1 per cent, SFC transaction levy of 0.0027 per cent and SEHK transaction fee of 0.005 per cent), that is, the issue price of each share under the global offer to facilitate the return of some of the 20625000 shares borrowed from Xiwang Medical Management to cover the over-allotment of the international offer under the share borrowing agreement.

After deducting the underwriting fees and commissions and estimated expenses payable by the Company in respect of the partial exercise of the over-allotment option, the Company will receive a net payment of approximately HK $204.7 million in respect of the 20125000 additional shares to be issued and allotted after the partial exercise of the over-allotment option. The Company intends to pro rata use the net additional proceeds for the purposes set out in the section entitled "Future plans and use of proceeds-use of proceeds" in the prospectus.

The price stabilization period and price stabilization action for the global offering ended on 29 July 2021 (i.e. the 30th day after the deadline for submitting applications for the Hong Kong Public offering). Some of the over-allotment options not exercised by the Joint Global Coordinator (for itself and on behalf of the international underwriters) expired on 29 July 2021.

Immediately following the completion of the global offering and the partial exercise of the over-allotment option, the Company will continue to comply with the public shareholding requirement under Rule 8.08 (1) (a) of the listing rules.